Trials / Completed
CompletedNCT00266565
Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome
A Phase I/II Study of the Effect of Intravenous Anti-IL-5 (Mepolizumab) SB 240563 on the Outcome and Management of Hypereosinophilic Syndromes
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Children's Hospital Medical Center, Cincinnati · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Toxicity of anti-IL-5
Detailed description
The purpose of the study is to assess the toxicity of anti-IL-5, and to see whether it lowers peripheral blood eosinophils and/or tissue and whether it has a steroid and/or interferon sparing effect.
Conditions
- Hypereosinophilic Syndromes
- Eosinophilic Gastroenteritis
- Churg-Strauss Syndrome
- Eosinophilic Esophagitis
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mepolizumab | 10mg/kg (max 750 ml) once a month for 3 months |
Timeline
- Start date
- 2001-12-01
- Primary completion
- 2005-04-01
- Completion
- 2005-04-01
- First posted
- 2005-12-19
- Last updated
- 2020-07-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00266565. Inclusion in this directory is not an endorsement.